secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shattuck Labs, Inc. (STTK)
CIK:        0001680367
Form:       8-K
Filed at:   2022-08-11T23:59:59+00:00
Accession:  0001680367-22-000021
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shattuck Labs Q2 net loss $27.4M; cash runway into H2 2024; SL-172154 combo trials starting
--------------------------------------------------------------------------------

- Cash and equivalents $214.2M (Dec 2021: $268.8M); operations funded into second half of 2024.
- Net loss $27.4M ($0.65/share) vs $23.6M ($0.56) in Q2 2021; R&D expense rose to $23.0M from $14.9M.
- SL-172154 dose escalation in ovarian cancer reached 10.0 mg/kg; combo with liposomal doxorubicin starts Q3 2022.
- Phase 1A/B of SL-172154 in AML/HR-MDS enrolling; initial monotherapy and combo data expected 1H 2023.
- New clinical candidate from ARC or GADLEN platform expected to be announced in second half of 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680367/000168036722000021/0001680367-22-000021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680367/000168036722000021/sttk-20220811.htm
  HTML page:      https://secwatch.observer/filing/0001680367-22-000021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer